- Home
- CCBG vs XERS Comparison
CCBG vs XERS Comparison
Compare CCBG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- XERS
- Stock Information
- Founded
- CCBG 1895
- XERS 2005
- Country
- CCBG United States
- XERS United States
- Employees
- CCBG N/A
- XERS N/A
- Industry
- CCBG Major Banks
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- XERS Health Care
- Exchange
- CCBG Nasdaq
- XERS Nasdaq
- Market Cap
- CCBG 625.1M
- XERS 526.3M
- IPO Year
- CCBG N/A
- XERS 2018
- Fundamental
- Price
- CCBG $35.49
- XERS $3.75
- Analyst Decision
- CCBG Buy
- XERS Strong Buy
- Analyst Count
- CCBG 2
- XERS 4
- Target Price
- CCBG $39.00
- XERS $5.15
- AVG Volume (30 Days)
- CCBG 19.1K
- XERS 1.8M
- Earning Date
- CCBG 01-28-2025
- XERS 03-05-2025
- Dividend Yield
- CCBG 2.52%
- XERS N/A
- EPS Growth
- CCBG 1.63
- XERS N/A
- EPS
- CCBG 3.12
- XERS N/A
- Revenue
- CCBG $230,883,000.00
- XERS $187,361,000.00
- Revenue This Year
- CCBG N/A
- XERS $25.11
- Revenue Next Year
- CCBG $3.65
- XERS $19.29
- P/E Ratio
- CCBG $11.68
- XERS N/A
- Revenue Growth
- CCBG 4.53
- XERS 22.72
- 52 Week Low
- CCBG $25.45
- XERS $1.69
- 52 Week High
- CCBG $40.86
- XERS $4.10
- Technical
- Relative Strength Index (RSI)
- CCBG 39.44
- XERS 57.32
- Support Level
- CCBG $36.73
- XERS $3.51
- Resistance Level
- CCBG $37.44
- XERS $4.10
- Average True Range (ATR)
- CCBG 0.85
- XERS 0.17
- MACD
- CCBG -0.18
- XERS 0.03
- Stochastic Oscillator
- CCBG 1.77
- XERS 46.15
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.